The perioperative mortality for people with ruptured abdominal aortic aneurysms (RAAA) has not changed for two decades. Of patients who survive long enough to undergo open repair for ruptured aneurysms, half die (48%; 95% confidence interval [CI] 46 to 50). Randomized trials have shown that endovascular aneurysm repair (EVAR) for nonruptured abdominal aortic aneurysms decreases perioperative mortality compared with open repair. EVAR may similarly benefit patients with RAAA. We aimed to summarize studies of patients undergoing EVAR for ruptured aneurysms. Methods: Two reviewers searched Medline and EMBASE databases from 1994 to July 2006, Cochrane Database of Systematic Reviews, the Database of Abstracts of Reviews of Effectiveness, the Cochrane Central Register of Controlled Trials, Best Evidence 1994 to 2006, reference lists, clinical trial registries, and conference proceedings; we also contacted authors. All published and unpublished studies in which a group of people with ruptured aneurysms, assessed objectively by imaging, was treated with EVAR (REVAR) were eligible. We used the generic inverse variance function of the REVMAN software to pool results for death in hospital. Sensitivity analyses, using prespecified subgroups, explored heterogeneity between studies. Results: Pooled mortality in 18 observational studies describing 436 people who underwent REVAR was 21% (95% CI 13 to 29); however, 90% of the heterogeneity between studies was not explained by chance alone. Surgical volume explained substantial heterogeneity. According to study-specific criteria, 47% (95% CI 39 to 55) of people with ruptured aneurysms were potentially eligible for REVAR.
Abdominal aortic aneurysms occur in 1% (95% confidence Interval [CI] 1 to 2) of women and 6% (95% CI 5 to 6) of men over the age of 64 years. 1 In a population study in Malmo, Sweden, the incidence of ruptured aneurysms increased from 5.6 per 100,000 person-years in 1971 to 1986 (95% CI 4.9 to 6.3) to 10.6 per 100,000 patientyears in 2000 to 2004 (95% CI 8.9 to 12.4). 2 Mortality of people with ruptured aneurysms is 85% (95% CI 80 to 91), of which 66% (95% CI 58 to 73) die before reaching hospital or without operation. 3 Perioperative mortality in people who underwent open repair was 48% (95% CI 46 to 50) in a meta-analysis of 171 observational studies, 4 and 41% (95% CI 40 to 42) in a recent population-based study. 5 The mortality of open repair of ruptured aneurysms has not improved significantly in the last two decades. 6 Endovascular aneurysm repair (EVAR) is the luminal exclusion of an aneurysm from circulatory flow using a conduit (endograft) inserted from a remote access vessel and deployed under fluoroscopic guidance. Two randomized trials in people with asymptomatic aneurysms reported a reduced risk of perioperative death with EVAR compared with open repair (pooled relative risk [RR] 0.34, 95% CI 0.17 to 0.67, P ϭ 0.002). 7, 8 Given the high perioperative mortality of open repair for people with ruptured aneurysms and the less invasive nature of EVAR compared with open repair, we conducted this systematic review to address the hypothesis that endovascular repair of ruptured aneurysms (REVAR) might be associated with lower mortality than open repair.
EVAR of ruptured aneurysms (REVAR) was first performed in April 1994 9 and first published by another group later that year. 10 To our knowledge, a single randomized controlled trial of 32 people has been conducted. 11 The rest of the evidence is observational. The most recent previous review was published 4 years ago, was not conducted systematically, did not describe study quality, and did not provide a metaanalysis of outcome data. 12 We conducted a systematic review to answer the question: in people with ruptured aneurysms undergoing endovascular aneurysm repair, what is the inhospital mortality and morbidity?
METHODS
We used guidelines from the meta-analysis of observational studies conference. 13 Our checklist is available online (Table I , online only).
These quality issues have specific importance in this review: a well-defined control group would improve generalizability by providing a description of the population of patients presenting with RAAA, prospective data collection may be more complete than that done retrospectively, blinded outcome assessors would be less likely to bias results, prespecified outcomes provide a systematic framework for prospective outcome assessment, the use of a clinical algorithm is a surrogate indicator of a well-organized team and the source of funding has been shown to influence results. 15 Data extraction. Data were collected independently by two reviewers with content and methodologic expertise (TMM, LGO) using an electronic extraction form. On two occasions, 2 weeks apart, we contacted authors of unpublished reports, conference proceedings, and papers with incomplete data to request information that was missing from published work.
Selection of outcomes and meta-analysis. We chose in-hospital mortality as the primary outcome. We also extracted data on associated morbidities, including renal morbidity, defined as patients requiring dialysis (both temporary and permanent) and patients who developed elevations in creatinine but did not require dialysis, paraplegia, and abdominal compartment syndrome. We recorded the proportion of all patients who presented with ruptured aneurysms who were treated with REVAR and assessed reasons for ineligibility, if provided by the authors. Mortality at long term follow-up was recorded where available.
Potential sources of heterogeneity and sensitivity analyses. We performed three prespecified sensitivity analysis in the hope of explaining some of the anticipated heterogeneity:
19 the direction of inquiry, the use of a systematic algorithm to determine eligibility for EVAR, and the expertise of surgeons and their endovascular teams (based on the volume of REVAR procedures described in each report). A cut point of 30 procedures was used to define expertise based on a recent cumulative sum (CUSUM) analysis showing that complication rates stabilize after 31 procedures.
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Statistics. We expressed agreement for eligibility and quality decisions using Cohen's Kappa (SPSS, Version 12.0, Chicago, Ill). Outcome data were pooled using the generic inverse variance function of Review Manager (Review Manager, Version 4.2, Cochrane Collaboration). We used the I 2 statistic to quantify heterogeneity and, in anticipation of high heterogeneity associated with observational studies, 19 we did not prespecify a level of I 2 that would justify pooling results.
RESULTS

Search.
After deduplication, we identified 3070 citations. Medline and EMBASE citations overlapped by 24%. Kappa for eligibility decisions was 0.71. We retrieved fulltext for 114 citations, which yielded 18 independent cohort studies with more than 10 participants (17 papers and one abstract: Fig 1) . All the potentially-relevant studies were written in English.
Study characteristics. Table II shows the characteristics of included studies. Tabulation of excluded studies is shown in Table III, online only. Table IV summarizes  clinical variables. Study methodology and quality assessment. Table  V , online only, summarizes the quality of the included studies. A control group was not described in seven studies, [21] [22] [23] [24] [25] [26] [27] was a historic cohort of patients undergoing open repair in three studies, [28] [29] [30] was a group of patients with symptomatic AAA in one study, 31 was a concurrent cohort of patients who were ineligible for REVAR (anatomically unsuitable or hemodynamically unstable) in two studies, 32, 33 was a concurrent cohort of patients who were either ineligible for REVAR or who, though eligible, underwent open repair because equipment or staff were lacking at the time of their presentation in two studies, 34, 35 was a concurrent cohort whose selection was not described in two studies, 36, 37 and a combination of patients undergoing REVAR prior to implementation of an algorithm and a historical and concurrent group of patients undergoing open repair in one. 38 No study included in this review reported a control group comprised entirely of concurrent patients who were eligible for REVAR who underwent open repair.
The direction of inquiry was retrospective in eight studies, 21, [28] [29] [30] 34, 36, 37 prospective in nine studies 22, [25] [26] [27] [31] [32] [33] 35, 38 and not reported in one study. 24 None of the included studies reported blinding of the outcome assessors. Outcomes were prespecified in nine studies (50%). 23, 29, 30, [32] [33] [34] [35] [36] 38 An algorithm to assess patients' eligibility for REVAR was used in 14 studies (72%). [21] [22] [23] [24] 26, [28] [29] [30] [31] [32] [33] 35, 37, 38 Funding sources were reported in two studies (11%). 25, 33 Funding was undeclared in 16 studies, 10 of which declared "no conflict of interest". [22] [23] [24] 27, [29] [30] [31] [38] [39] [40] Primary results and sensitivity analyses. In the 18 observational studies included in this review, in-hospital mortality for patients who underwent REVAR varied from 0% (95% CI 0 to 28) 30 to 45% (95% CI 23 to 67) 25 (Fig 2) . Pooled mortality was 21% (95% CI 13 to 29), though heterogeneity (I 2 ) was high, 90.2%. Heterogeneity was explored in three sensitivity analyses. In-hospital mortality for prospective studies was 23% (95% CI 15 to 31) compared with retrospectively reported studies, which was 19% (95% CI 7 to 30). The I 2 value for the prospective studies decreased to 64.5% (Fig 3) .
In the 14 studies that included details of the algorithm used, the pooled in-hospital mortality was 18% (95% CI 10 to 26; I 2 86.9%). For studies that did not report using an algorithm, it was 32% (95% CI 20 to 44; I 2 90.2%) (Fig 4) . In a subgroup analysis by surgical volume (as a surrogate for expertise; assessed as Ͼ30 cases reported), the in-hospital mortality for groups that reported more than 30 REVAR is 19% (95% CI 10 to 28; I 2 57.1%) and for those that reported 30 or fewer procedures, 22% (95% CI 12 to 33; I 2 90.3 %) (Fig 5) . Details of algorithms for selection of patients for REVAR. A summary of selection criteria for REVAR and reasons for patients' ineligibility for REVAR is found in Table VI , online only. In six studies, the presence of an endovascular specialist was required. 25, 29, [31] [32] [33] 38 CT scans were required if the patient was hemodynamically stable in all but two studies. 25, 26 A threshold systolic blood pressure or hemodynamic parameters that mandated abandoning REVAR in favor of emergency laparotomy were explicitly stated in two studies. 33, 38 Using a random effects model, 53% (95% CI 45 to 61; I 2 54%) of patients were ineligible for REVAR (Fig 6; Table VII ), a figure that includes patients deemed ineligible because resources for REVAR were not available at the time of their presentation (12% of people in studies reporting this issue). Details of management protocols. Permissive hypotension, also described as hypotensive hemostasis by some authors, a resuscitation technique in which the administration of intravenous fluids and blood is limited to maintain a lower systolic blood pressure, usually according to a protocol, was used in 13 studies. [21] [22] [23] [24] [25] [26] [27] 29, 31, 33, 35, 37, 38 No authors recommended the routine use of an aortic occlusion balloon. Critical aortic dimensions were specified as aspects of anatomic eligibility criteria in nine studies. 22, 24, 25, [29] [30] [31] [32] [33] 35 Adverse events and long-term follow-up. Table  VIII , online only, describes major adverse events. Most authors did not report standardized definitions to classify outcomes: one author reported a definition for renal failure not requiring dialysis, 27 and one author used a published classification system for paraplegia. 23 Some authors reported mortality for various durations of long-term follow-up (Table IX , online only). Because of the low number of events and the lack of standard definitions, we decided not to pool results for adverse events or long-term mortality.
DISCUSSION
The pooled estimate of mortality for REVAR, based on observational studies included in this systematic review, is 21% (95% CI 13 to 29), but substantial heterogeneity between studies exists (I 2 90.2%), and reliance should not be placed on the point estimate. Differences in study quality alone cannot account for the heterogeneity, but restricting the analysis to studies of teams with greater surgical experience did lead to substantial reduction in heterogeneity (I 2 57.1%), though not to the point conventionally considered acceptable for accepting a pooled analysis (Ͻ 50%). Strengths and weaknesses of this work. This work represents, to our knowledge, the first systematic attempt to summarize results of observational studies of endovascular repair of ruptured aneurysms. We conducted a sensitive search using multiple databases and extracted data in duplicate. We assessed quality in the studies according to six items on which we reached consensus before data extraction. We hypothesized that control groups would be variable in their composition and that many would be clearly biased: the data confirmed our concerns and justified our decision to summarize only the REVAR arms of the controlled comparisons reported. However, the methodologic quality of the studies included was low (Table IV) , and heterogeneity was substantial.
Relationship of this work to other studies. We observed less heterogeneity between results when divided according to surgical volume, though the point estimates for mortality did not differ between groups with larger or smaller volumes. This observation adds to other data that support the importance of experience in REVAR. 38 Further information on mortality in REVAR is available from Medicare databases, which are excluded from the formal meta-analysis because they included patients from the individual clinical studies. For the United States as a whole, for a 5% sample of US inpatients, for patients from Illinois, and for patients from New York, California, Florida, and New Jersey combined, mortality with REVAR has been reported to be 53%, 33%, 36%, and 39%, respectively. 36, [41] [42] [43] These rates are higher than those in our summary. We excluded case series of 10 of fewer patients, since we felt these results would likely be biased in that investigators were more likely to report, and journals to publish, small series if their results were good. However, in excluding these studies, we have limited our analysis to the work of groups with larger volumes and, therefore, possibly better outcomes because of greater experience. It is not possible to determine from the data at hand whether the difference between registry rates and our summary of the larger individual studies represents chance, publication bias, or the effect of greater expertise in centers with larger volumes.
We hypothesized a priori that studies reporting the use of algorithms to assess patients for eligibility for REVAR might show better outcomes than those without algorithms, either because appropriate patient selection is essential to technical success, or because the use of an algorithm is a surrogate for an organized approach to the problem, and a marker of quality of overall care. Mortality was 18% (95% CI 10 to 26; I 2 86.9%) in studies reporting an algorithm and 32% (95% CI 20 to 44; I 2 90.2%) in those without. Confidence intervals overlap, but the difference in the point estimates are consistent with a single center report of mortality of 29% (95% CI 19 to 40) before the implementation of an algorithm and 13% (95% CI 2 to 23) afterwards. 38 Common elements of algorithms were a strategy for permissive hypotension, CT scanning before intervention if the patient's condition permitted, anatomic eligibility criteria similar to those used in the assessment for elective repair, a hemodynamic threshold for conversion to open repair, and the involvement of a trained team.
By design, an algorithm selects the most stable patients to undergo REVAR. In our review, 47% of patients were eligible, and some of the ineligible patients were so classified for administrative rather than clinical reasons (12% of those in studies reporting this data; Table VII, online only). We did not perform statistical comparisons of patients treated with REVAR with those in the control groups reported as we felt the composition of the control groups was too biased to permit meaningful comparison. Historically, the mortality rate for patients with ruptured aneurysms who undergo open surgery is 41% to 49%. 4, 5 Centers that report outcomes for all RAAAs after the introduction of REVAR have published mortality rates of 24% to 46%. 34, 35, 44 A randomized trial (published after our cut-off date for inclusion of studies) screened 103 patients and randomized 32 to immediate open surgery or to consideration for REVAR. Mortality was 53% (95% CI 29 to 77) in the group assigned to open and 53% (95% CI 28 to 79) in the REVAR group, but the sample size was too small to draw statistically significant conclusions. 11 It is not possible to conclude from our own work or from these related studies whether the low pooled mortality we observed (21% [95% CI 13 to 29]) is due to chance, due to selection of patients for REVAR, or due to benefit from the technique in improving outcomes.
Implications of the study for clinical practice. Though it is not possible to conclude that the results in patients treated with REVAR are better than those for open surgery, this work offers support for this technique in patients in centers where adequate expertise and resources are available without incurring delay. We hope that our summary of accumulated experience with REVAR will be useful to those who are planning or running endovascular programs as a synthesis of the published experience and by providing insight into different practices. A summary of algorithms used in different centers is available online (Table VII, online only). Unanswered questions and implications for research. We believe that the evidence summarized here is inadequate to recommend widespread adoption of strategies that include REVAR, and that a large multicenter randomized trial comparing such a strategy with open repair is needed. In the interim, we recommend continued reporting of observational results. Ideally, centers in which REVAR is employed should contribute data to a central registry. We have identified opportunities for improvement in the quality of reporting of nonrandomized studies of this technique. In the published literature, the selection of controls has been particularly problematic. We suggest that a suitable control group comprises those patients who were eligible for REVAR according to center-specific protocols but who did not undergo the procedure because of administrative reasons or resource constraints. Describing results for subgroups of patients categorized according to hemodynamic stability, in both REVAR and control groups, will begin to address the issue of which patients might benefit most from REVAR. It is possible that subgroups of patients, perhaps those who are very unstable hemodynamically, or whose previous intra-abdominal pathology strongly contraindicates open repair, will benefit most from this technique: data on these issues should be included in any registry and in future publications. We also recommend reporting of overall event rates for consecutive patients presenting with RAAA, regardless of treatment method. Finally, long-term outcomes over years to decades, addressed in only a few of the studies summarized here, should be included in future reports as they become available.
CONCLUSIONS
Short-term mortality after endovascular repair of ruptured aneurysms appears promising in the selected patients who have undergone the procedure. Further research is needed to refine the indications for REVAR in patients presenting with RAAA.
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